Dapagliflozin in Acute Heart failure

Efficacy of Dapagliflozin in diabetic and nondiabetic patients with Acute heart failure

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220529055013N1

Enrollment

160

Registered

2022-06-23

Start date

2022-07-01

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with reduced ejection fraction.

Interventions

Intervention 1: Intervention group: Tab Dapagliflozin 10 mg orally as add on therapy to the conventional treatment will be prescribed to the study participants. Intervention 2: Control group: The part

Eligibility

Sex/Gender

All

Age

30 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Male/Female patients 30 years and above 2. Diagnosis of acute decompensated heart failure made on admission based on any two of the following signs and symptoms a)Dyspnea at rest or minimal exertion b)Peripheral edema c) Ascites d)5-pound weight gain (rapid) e) Signs of congestion on X-ray 3. Left ventricular Ejection fraction = 40% 4. eGFR = 30ml/min

Exclusion criteria

Exclusion criteria: Cardiogenic shock; urgent hospitalization for acute heart failure primarily triggered by pulmonary embolism ,cerebrovascular accident, or acute myocardial infarction Current hospitalization for acute heart failure not caused primarily by intravascular volume overload Type 1 Diabetes mellitus History of Diabetic ketoacidosis History of hepatic impairment Known allergy to SGLT 2 inhibitors Women pregnant or breast feeding

Design outcomes

Primary

Measure	Time frame
Effect of drug on kidney function. Timepoint: At day 0, 1, 7 and 30. Method of measurement: estimated glomerular filtration rate ( eGFR).;Improvement in symptoms and quality of life of heart failure patients admitted with acute decompensation. Timepoint: At admission( baseline), followed at Day 1,day7 and day 30. Method of measurement: Kansas city cardiomyopathy questionnaire (KCCQ).	—

Secondary

Measure	Time frame
Improvement in Hemoglobin levels. Timepoint: Day 0, 1, 7 and day 30. Method of measurement: complete blood count.;Blood pressure. Timepoint: Day 0,1 7 and 30. Method of measurement: Sphygmamometer.	—

Countries

Pakistan

Contacts

Public ContactSyedahh Fauzia Fatima Gilani

National University of medical Sciences

fauziagilani@gmail.com+92 51 2300714

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026